Received: 16 November 2020
Accepted: 6 January 2021
First Online: 19 January 2021
Ethics approval and consent to participate
: This study was approved by the Cantonal Ethics Committee (BASEC-Nr 2017-02115). Written informed consent was obtained from all patients.
: Not applicable.
: OD: consultancy relationship and/or received research funding (last 3 years) from Abbvie, Actelion, Acceleron Pharma, Amgen, AnaMar, Baecon Discovery, Blade Therapeutics, Bayer, Boehringer Ingelheim, Catenion, Competitive Drug Development International Ltd., CSL Behring, ChemomAb, Curzion Pharmaceuticals, Ergonex, Galapagos NV, Glenmark Pharmaceuticals, GSK, Inventiva, Italfarmaco, iQone, iQvia, Lilly, medac, Medscape, Mitsubishi Tanabe Pharma, MSD, Novartis, Pfizer, Roche, Sanofi, Target BioScience and UCB in the area of potential treatments of scleroderma and its complications. In addition, OD has a patent mir-29 for the treatment of systemic sclerosis issued (US8247389, EP2331143).PH: speaker fee: Grünenthal Pharma AG, Nevro Medical Ltd.CM: Consultancy fees from Boehringer-Ingelheim and mepha, as well as congress support from Roche and Actelion.RD: grants from Articulum Fellowship, sponsored by Pfizer (2013-2014), and Actelion; speaker fees from Actelion and consultancy fees from Boehringer-Ingelheim in the field of systemic sclerosis, outside the submitted work.BM: grant/research support from AbbVie, Protagen and Novartis Biomedical Research and speaker fees from Boehringer-Ingelheim as well as congress support from Pfizer, Roche, Actelion, mepha and MSD. In addition, BM has a patent mir-29 for the treatment of systemic sclerosis issued (US8247389, EP2331143).